Pentamidine isethionate and Pneumocystis jiroveci infection - a phase IV clinical study of FDA data


Pneumocystis jiroveci infection is found among people who take Pentamidine isethionate, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Pentamidine isethionate and have Pneumocystis jiroveci infection. It is created by eHealthMe based on reports of 1,832 people who have side effects when taking Pentamidine isethionate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2022

1,832 people reported to have side effects when taking Pentamidine isethionate.
Among them, 8 people (0.44%) have Pneumocystis jiroveci infection.

What is Pentamidine isethionate?

Pentamidine isethionate has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,834 Pentamidine isethionate users for its effectiveness, alternative drugs and more.

What is Pneumocystis jiroveci infection?

Pneumocystis jiroveci infection (fungal infection of the lungs) is found to be associated with 265 drugs and 156 conditions by eHealthMe.

Number of Pentamidine isethionate and Pneumocystis jiroveci infection reports submitted per year:

Could Pentamidine isethionate cause Pneumocystis jiroveci infection?

Time on Pentamidine isethionate when people have Pneumocystis jiroveci infection *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Pneumocystis jiroveci infection when taking Pentamidine isethionate *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Pneumocystis jiroveci infection when taking Pentamidine isethionate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 100 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Pentamidine isethionate *:

  1. Zovirax: 7 people, 87.50%
  2. Viracept: 7 people, 87.50%
  3. Retrovir: 7 people, 87.50%
  4. Epivir: 7 people, 87.50%
  5. Clarithromycin: 6 people, 75.00%
  6. Zerit: 5 people, 62.50%
  7. Epzicom: 5 people, 62.50%
  8. Cotrim: 4 people, 50.00%
  9. Lamivudine And Zidovudine: 4 people, 50.00%
  10. Stavudine: 2 people, 25.00%

Common side effects people have besides Pneumocystis jiroveci infection *:

  1. Urine Abnormality: 7 people, 87.50%
  2. Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 7 people, 87.50%
  3. Constipation: 7 people, 87.50%
  4. Diabetes: 7 people, 87.50%
  5. Anaemia (lack of blood): 7 people, 87.50%
  6. Genital Herpes (herpes infection of genital): 4 people, 50.00%
  7. Hyperglycemia (high blood sugar): 3 people, 37.50%
  8. Herpes Simplex (herpes simplex is a common viral infection): 3 people, 37.50%
  9. Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 1 person, 12.50%
  10. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 1 person, 12.50%

Common conditions people have *:

  1. Hiv Infection: 7 people, 87.50%
  2. Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 3 people, 37.50%
  3. Enterococcal Infection: 1 person, 12.50%
  4. Clostridial Infection (infectious conditions by clostridium bacteria): 1 person, 12.50%
  5. Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Pentamidine isethionate and have Pneumocystis jiroveci infection?

Check whether Pneumocystis jiroveci infection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Pneumocystis jiroveci infection and when was it recovered:

Expand to all the drugs that have ingredients of pentamidine isethionate:

Alternative drugs to, pros and cons of Pentamidine isethionate:

Common Pentamidine isethionate side effects:

Browse all side effects of Pentamidine isethionate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Pneumocystis jiroveci infection treatments and more:

COVID vaccines that are related to Pneumocystis jiroveci infection:

All the drugs that are associated with Pneumocystis jiroveci infection:

All the conditions that are associated with Pneumocystis jiroveci infection:

How the study uses the data?

The study uses data from the FDA. It is based on pentamidine isethionate (the active ingredients of Pentamidine isethionate) and Pentamidine isethionate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: